<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28685973</article-id><article-id pub-id-type="pmc">5724491</article-id><article-id pub-id-type="doi">10.1111/dom.13056</article-id><article-id pub-id-type="publisher-id">DOM13056</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes</article-title><alt-title alt-title-type="left-running-head">Wysham et al.</alt-title></title-group><contrib-group><contrib id="dom13056-cr-0001" contrib-type="author" corresp="yes"><name><surname>Wysham</surname><given-names>Carol H.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3056-0047</contrib-id><address><email>cwysham@rockwoodclinic.com</email></address><xref ref-type="aff" rid="dom13056-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13056-cr-0002" contrib-type="author"><name><surname>Rosenstock</surname><given-names>Julio</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13056-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13056-cr-0003" contrib-type="author"><name><surname>Vetter</surname><given-names>Marion L.</given-names></name><degrees>MD, MS, RD</degrees><xref ref-type="aff" rid="dom13056-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13056-cr-0004" contrib-type="author"><name><surname>Dong</surname><given-names>Fang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13056-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13056-cr-0005" contrib-type="author"><name><surname>&#x000d6;hman</surname><given-names>Peter</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13056-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13056-cr-0006" contrib-type="author"><name><surname>Iqbal</surname><given-names>Nayyar</given-names></name><degrees>MD, MSCE</degrees><xref ref-type="aff" rid="dom13056-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="dom13056-aff-0001" content-type="private-address">
<label><sup>1</sup></label>
<institution>Rockwood Clinic</institution>
<named-content content-type="city">Spokane</named-content>
<named-content content-type="country-part">Washington</named-content>
</aff><aff id="dom13056-aff-0002" content-type="private-address">
<label><sup>2</sup></label>
<institution>Dallas Diabetes Research Center at Medical City</institution>
<named-content content-type="city">Dallas</named-content>
<named-content content-type="country-part">Texas</named-content>
</aff><aff id="dom13056-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<institution>Bristol&#x02010;Myers Squibb</institution>
<named-content content-type="city">Princeton</named-content>
<named-content content-type="country-part">New Jersey</named-content>
</aff><aff id="dom13056-aff-0004" content-type="private-address">
<label><sup>4</sup></label>
<institution>AstraZeneca</institution>
<named-content content-type="city">Gaithersburg</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Carol H. Wysham MD, Rockwood Center for Diabetes and Endocrinology, 400 East Fifth Avenue, Spokane, Washington 99202. Email: <email>cwysham@rockwoodclinic.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2018</year></pub-date><volume>20</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-1</issue-id><fpage>165</fpage><lpage>172</lpage><history><date date-type="received"><day>14</day><month>2</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-165.pdf"/><abstract><sec id="dom13056-sec-0001"><title>Aims</title><p>To simplify administration of aqueous exenatide once weekly, which requires reconstitution, the exenatide microspheres have been reformulated in a ready&#x02010;to&#x02010;use autoinjector with a <styled-content style="fixed-case">M</styled-content>iglyol diluent (exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content>). This study compared the efficacy and safety of exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content> with the first&#x02010;in&#x02010;class glucagon&#x02010;like peptide&#x02010;1 receptor agonist exenatide twice daily (<styled-content style="fixed-case">BID</styled-content>).</p></sec><sec id="dom13056-sec-0002"><title>Materials and <styled-content style="fixed-case">M</styled-content>ethods</title><p>This randomized, open&#x02010;label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose&#x02010;lowering medication randomized patients 3:2 to either exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content> (2&#x02009;mg) or exenatide BID (10&#x02009;&#x003bc;g) for 28&#x02009;weeks. The primary outcome was the 28&#x02010;week change in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>). A subset of patients completed a standardized meal test for postprandial and pharmacokinetic assessments.</p></sec><sec id="dom13056-sec-0003"><title>Results</title><p>A total of 375 patients (mean <styled-content style="fixed-case">HbA1c</styled-content>, 8.5% [69&#x02009;mmol/mol]; body mass index, 33.2&#x02009;kg/m<sup>2</sup>; diabetes duration, 8.5&#x02009;years) received either exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content> (n&#x02009;=&#x02009;229) or exenatide <styled-content style="fixed-case">BID</styled-content> (n&#x02009;=&#x02009;146); <styled-content style="fixed-case">HbA1c</styled-content> was reduced by &#x02212;1.4% and &#x02212;1.0%, respectively (least&#x02010;squares mean difference, &#x02212;0.37%; <styled-content style="italic-in-any-context">P</styled-content>&#x02009;=&#x02009;.0072). More patients achieved <styled-content style="fixed-case">HbA1c</styled-content>&#x02009;&#x0003c;7.0% with exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content> (49.3%) than with exenatide <styled-content style="fixed-case">BID</styled-content> (43.2%; <styled-content style="italic-in-any-context">P</styled-content>&#x02009;=&#x02009;.225). Body weight was reduced in both groups (<styled-content style="italic-in-any-context">P</styled-content>&#x02009;=&#x02009;.37 for difference). Gastrointestinal adverse events (<styled-content style="fixed-case">AE</styled-content>s) were reported in 22.7% (exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content>) and 35.6% (exenatide <styled-content style="fixed-case">BID</styled-content>) of patients; fewer patients in the exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content> group withdrew because of <styled-content style="fixed-case">AE</styled-content>s than in the exenatide <styled-content style="fixed-case">BID</styled-content> group. Minor hypoglycaemia occurred most often with concomitant sulfonylurea use.</p></sec><sec id="dom13056-sec-0004"><title>Conclusions</title><p>Exenatide <styled-content style="fixed-case">QWS&#x02010;AI</styled-content> was associated with a greater reduction in <styled-content style="fixed-case">HbA1c</styled-content>, similar weight loss and a favorable gastrointestinal <styled-content style="fixed-case">AE</styled-content> profile compared with exenatide <styled-content style="fixed-case">BID</styled-content>.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13056-kwd-0001">autoinjector</kwd><kwd id="dom13056-kwd-0002">exenatide</kwd><kwd id="dom13056-kwd-0003">glucagon&#x02010;like peptide&#x02010;1 receptor agonist</kwd><kwd id="dom13056-kwd-0004">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Bristol&#x02010;Myers Squibb</funding-source></award-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="8"/><word-count count="5429"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13056</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.8 mode:remove_FC converted:11.12.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom13056-cit-1001">
<string-name>
<surname>Wysham</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vetter</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>&#x000d6;hman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Iqbal</surname>
<given-names>N.</given-names>
</string-name>
<article-title>Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;<volume>20</volume>:<fpage>165</fpage>&#x02013;<lpage>172</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13056">https://doi.org/10.1111/dom.13056</ext-link>
<pub-id pub-id-type="pmid">28685973</pub-id></mixed-citation>
</p><fn-group id="dom13056-ntgp-0101"><fn id="dom13056-note-0101"><p>
<bold>Funding information</bold> This study was supported by Bristol&#x02010;Myers Squibb and AstraZeneca.</p></fn></fn-group></notes></front><body><sec id="dom13056-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Patients with type 2 diabetes require long&#x02010;term treatment to achieve and maintain glycaemic control; thus, the availability of therapeutic options that are effective and simple to administer is important. The initial formulation of exenatide, a first&#x02010;in&#x02010;class glucagon&#x02010;like peptide&#x02010;1 receptor agonist (GLP&#x02010;1RA) that has been used clinically for over 10&#x02009;years, is still available but requires twice&#x02010;daily (BID) subcutaneous administration (exenatide BID). Subsequently, exenatide was packaged into biodegradable poly&#x02010;(<sc>d,l</sc>&#x02010;lactide&#x02010;co&#x02010;glycolide) microspheres that allow for once&#x02010;weekly (QW) administration but require reconstitution in an aqueous diluent before injection. A single dose of exenatide QW results in the gradual release of exenatide from the microspheres over approximately 10&#x02009;weeks.<xref rid="dom13056-bib-0001" ref-type="ref">1</xref> When administered every 7&#x02009;days, the therapeutic threshold is reached after 2&#x02009;weeks, and steady&#x02010;state plasma concentrations are achieved after approximately 7&#x02009;weeks.<xref rid="dom13056-bib-0002" ref-type="ref">2</xref> Patients receiving exenatide QW over time have demonstrated sustained reductions from baseline in glycated haemoglobin (HbA1c) and body weight.<xref rid="dom13056-bib-0003" ref-type="ref">3</xref>, <xref rid="dom13056-bib-0004" ref-type="ref">4</xref>
</p><p>To improve ease of use, development efforts were directed at simplifying the delivery of exenatide&#x02010;containing microspheres by eliminating the need for reconstitution in aqueous diluent before administration. Exenatide QW suspension by autoinjector (exenatide QWS&#x02010;AI) contains exenatide microspheres in a mixture of medium&#x02010;chain triglycerides (Miglyol 812), which is recognized as safe by the US Food and Drug Administration and is approved for use in a variety of drugs, foods and cosmetics in the USA and Europe. The new formulation allows for easier administration of exenatide QW via an autoinjector.</p><p>This study compared the efficacy, safety and tolerability of exenatide QWS&#x02010;AI with the original exenatide BID formulation over 28&#x02009;weeks of treatment in patients with type 2 diabetes.</p></sec><sec id="dom13056-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="dom13056-sec-0007"><label>2.1</label><title>Patients and study design</title><p>This phase III, randomized, controlled, open&#x02010;label study (DURATION&#x02010;NEO&#x02010;1; <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01652716), conducted at 65 sites in the USA, compared the efficacy, safety and tolerability of exenatide QWS&#x02010;AI with that of exenatide BID. The initial controlled treatment period was 28&#x02009;weeks. A 52&#x02010;week extension will be reported separately. Patients were aged &#x02265;18&#x02009;years and had type 2 diabetes. They were treated with diet and exercise alone or with a stable regimen of metformin, sulfonylurea, pioglitazone or any combination of 2 of these agents. They had an HbA1c level of 7.1% to &#x02264;11.0% (54&#x02010;97&#x02009;mmol/mol). Patients were excluded if they had a clinically significant medical condition, including a history of pancreatitis or renal transplantation, current or past family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, severe renal impairment (estimated glomerular filtration rate [eGFR]&#x02009;&#x0003c;&#x02009;30&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>) or were receiving dialysis, or active cardiovascular disease within 3&#x02009;months of screening.</p><p>Patients were stratified by background diabetes therapy (diet and exercise alone, sulfonylurea use [&#x000b1; metformin and/or pioglitazone] or non&#x02013;sulfonylurea use [metformin and/or pioglitazone]), HbA1c (&#x0003c;9.0% or &#x02265;9.0% [&#x0003c;75 or &#x02265;75&#x02009;mmol/mol]) and renal function (normal [eGFR &#x02265;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>], mild renal impairment [eGFR 60&#x02010;89&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>] or moderate renal impairment [eGFR 30&#x02010;59&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>]) at screening. They were randomized in a 3:2 ratio to treatment with exenatide QWS&#x02010;AI or exenatide BID, respectively. Randomization was done centrally through an interactive web system by study&#x02010;site personnel.</p><p>Upon randomization, patients received injections of either exenatide QWS&#x02010;AI (2&#x02009;mg) with a 23&#x02010;gauge needle<xref rid="dom13056-bib-0001" ref-type="ref">1</xref> or exenatide BID (5&#x02009;&#x003bc;g for 4&#x02009;weeks, 10&#x02009;&#x003bc;g subsequently; administered 60&#x02009;minutes before morning and evening meals) with a 29&#x02010; to 31&#x02010;gauge needle.<xref rid="dom13056-bib-0005" ref-type="ref">5</xref> Prior concomitant glucose&#x02010;lowering medications were continued at pretrial doses, and patients continued prescribed diet and exercise regimens. Investigators initiated rescue medication for patients who experienced a loss of glucose control (2 consecutive visits with fasting plasma glucose [FPG]&#x02009;&#x0003e;&#x02009;270&#x02009;mg/dL [&#x0003e;15.0&#x02009;mmol/L] from weeks 4&#x02010;16 or &#x0003e;240&#x02009;mg/dL [&#x0003e;13.3&#x02009;mmol/L] from weeks 16&#x02010;28). Drug choice was left to the investigator's discretion and followed local prescribing practices.</p><p>A subset of patients from select study sites also participated in a standardized meal test to assess postprandial glycaemic and pharmacokinetic measures. Meal test assessments were completed at baseline and at 16&#x02009;weeks.</p><p>The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board for each study site. All patients provided written informed consent.</p></sec><sec id="dom13056-sec-0008"><label>2.2</label><title>End points and assessments</title><p>The primary efficacy end point for the study was change in HbA1c from baseline (randomization) to week 28. Secondary efficacy end points included the proportion of patients achieving HbA1c&#x02009;&#x0003c;&#x02009;7.0% (&#x0003c;53&#x02009;mmol/mol) by 28&#x02009;weeks, change in FPG and body weight from baseline to week 28, and change in 2&#x02010;hour postprandial glucose (PPG) from baseline to week 16 in a subgroup of patients enrolled in the meal test cohort. An exploratory analysis of the change in HbA1c, FPG and body weight from baseline to week 28 was also conducted in patients using sulfonylureas vs those not using sulfonylureas. Additional efficacy measures included the proportion of patients achieving HbA1c&#x02009;&#x02264;&#x02009;6.5% (&#x02264;48&#x02009;mmol/mol) after 28&#x02009;weeks and changes from baseline to week 28 in fasting insulin, glucagon and lipid concentrations, systolic and diastolic blood pressure (BP) and other cardiovascular risk biomarkers.</p><p>The primary safety and tolerability measure was incidence of reported adverse events (AEs), which was summarized descriptively. A clinical events classification committee was responsible for blinded review and adjudication of certain events. AEs of interest for the GLP&#x02010;1RA class were also monitored for duration and time course and included thyroid neoplasms (adjudicated), pancreatic cancer (adjudicated), renal failure, hypersensitivity reactions, immune&#x02010;related AEs, injection site&#x02010;related AEs, gastrointestinal AEs, hypoglycaemia, pancreatitis (adjudicated) and cardiovascular events (adjudicated). Severe hypoglycaemia was defined as any event requiring third&#x02010;party assistance because of severe impairment in consciousness or behavior that resolved after administration of glucagon or glucose. Minor hypoglycaemia was classified by symptoms consistent with hypoglycaemia and a glucose concentration &#x0003c;54&#x02009;mg/dL (&#x0003c;3&#x02009;mmol/L).</p><p>Clinical laboratory tests, including measures of renal function and liver function, were evaluated throughout the 28&#x02010;week treatment period. Anti&#x02010;exenatide antibodies were measured with an enzyme&#x02010;linked immunosorbent assay.<xref rid="dom13056-bib-0006" ref-type="ref">6</xref>
</p><p>For the meal test cohort, patients consumed a standardized breakfast meal (~660&#x02009;kcal [~2761.4&#x02009;kJ], mixed solid foods) containing approximately 60% carbohydrates, 15% protein and 25% fat, within 15&#x02009;minutes, Fasting measures, including glucose, glucagon, insulin and triglycerides, were obtained before meal consumption. Serial measurements of glucose, insulin and triglyceride concentrations were obtained over 5 hours. Change in 2&#x02010;hour PPG was also recorded. Pharmacokinetic analyses summarized plasma concentrations of exenatide, with the steady&#x02010;state concentration determined as the average plasma concentration from week 10 to week 28.</p></sec><sec id="dom13056-sec-0009"><label>2.3</label><title>Statistical methods</title><p>The target sample size was approximately 375 patients, with an anticipated withdrawal rate of 15% by week 28. A sample size of 225 patients randomized to receive exenatide QWS&#x02010;AI and 150 patients randomized to receive exenatide BID was estimated to provide &#x0003e;95% power to demonstrate that exenatide QWS&#x02010;AI is noninferior to exenatide BID (within a 0.4% noninferiority upper margin) in the HbA1c change from baseline to week 28, assuming a common standard deviation (SD) of 1.15% and an expected mean difference of &#x02212;0.1% or less (exenatide QWS&#x02010;AI &#x02212; exenatide BID).</p><p>The sample size was estimated to provide 91% power to show superiority of exenatide QWS&#x02010;AI in HbA1c change from baseline to week 28, assuming a common SD of 1.15% and a mean difference of &#x02212;0.4% (exenatide QWS&#x02010;AI &#x02212; exenatide BID).</p><p>The modified intention&#x02010;to&#x02010;treat (mITT) population, which comprised all randomized patients who received at least 1 dose of study drug, was used for efficacy and pharmacodynamic analyses. A full description of the study populations used for analysis is available online in Appendix S1.</p><p>Efficacy measures were summarized descriptively by treatment, and comparisons were made using the mixed&#x02010;effects model for repeated measures, with the exception of analysis of the proportion of patients achieving HbA1c goals (7.0% and 6.5% [53 and 48&#x02009;mmol/mol], respectively; Cochran&#x02013;Mantel&#x02013;Haenszel test) and change in 2&#x02010;hour PPG at week 16 (meal test cohort; general linear model). Further details on the models used for analysis are provided in Appendix S1. Change&#x02010;from&#x02010;baseline data are presented as the least&#x02010;squares mean and standard error of the least&#x02010;squares mean, and the difference in change between groups is reported as the least&#x02010;squares mean difference and standard error of the least&#x02010;squares mean difference, unless otherwise noted. A closed testing procedure was implemented to preserve the family&#x02010;wise type I error rate; noninferiority was evaluated first, and if achieved, superiority for the primary end point was assessed. For the primary end point, a 2&#x02010;sided significance level of 0.05 was used. Missing data were imputed using the last&#x02010;observation&#x02010;carried&#x02010;forward method. Incremental area under the curve was calculated to assess the postprandial response as a baseline&#x02010;subtracted measure of area under the curve for glucose, serum insulin and triglyceride measures.</p></sec></sec><sec id="dom13056-sec-0010"><label>3</label><title>RESULTS</title><sec id="dom13056-sec-0011"><label>3.1</label><title>Patients</title><p>The study, including the extension phase, was conducted from January 28, 2013 through March 26, 2015. A total of 377 patients were randomized to receive exenatide QWS&#x02010;AI (n&#x02009;=&#x02009;229) or exenatide BID (n&#x02009;=&#x02009;148) (Figure <xref rid="dom13056-fig-0001" ref-type="fig">1</xref>). Two patients in the exenatide BID group withdrew before the first dose of study medication (mITT population: exenatide QWS&#x02010;AI, n&#x02009;=&#x02009;229; exenatide BID, n&#x02009;=&#x02009;146). The treated population was identical to the mITT population. Compliance was high for both groups (see Appendix S1 for more details).</p><fig fig-type="Figure" xml:lang="en" id="dom13056-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patient disposition. Abbreviations: <styled-content style="fixed-case">BID</styled-content>, twice daily; <styled-content style="fixed-case">ITT</styled-content>, intention&#x02010;to&#x02010;treat; <styled-content style="fixed-case">QWS&#x02010;AI</styled-content>, once&#x02010;weekly suspension by autoinjector</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-165-g002"/></fig><p>Baseline characteristics were similar between treatment groups (Table <xref rid="dom13056-tbl-0001" ref-type="table-wrap">1</xref>). Patients were primarily male and white, with a baseline HbA1c of 8.5% (69&#x02009;mmol/mol). During the 28&#x02010;week assessment period, 23 patients (10%) in the exenatide QWS&#x02010;AI group and 22 patients (15%) in the exenatide BID group received new concomitant glucose&#x02010;lowering medication. This includes 5 patients (2.2%) in the exenatide QWS&#x02010;AI group and 6 patients (4.1%) in the exenatide BID group who met the protocol&#x02010;specified criteria for rescue medication.</p><table-wrap id="dom13056-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and baseline characteristics (modified intention&#x02010;to&#x02010;treat population)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">Exenatide QWS&#x02010;AI (n&#x02009;=&#x02009;229)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Exenatide BID (n&#x02009;=&#x02009;146)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex</td><td align="center" valign="top" rowspan="1" colspan="1">148 (65)</td><td align="center" valign="top" rowspan="1" colspan="1">92 (63)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1">56&#x02009;&#x000b1;&#x02009;10</td><td align="center" valign="top" rowspan="1" colspan="1">57&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Race</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">168 (73)</td><td align="center" valign="top" rowspan="1" colspan="1">110 (75)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td><td align="center" valign="top" rowspan="1" colspan="1">38 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (16)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td><td align="center" valign="top" rowspan="1" colspan="1">17 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">American Indian or Alaskan Native</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Native Hawaiian or other Pacific Islander</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ethnicity (Hispanic or Latino)</td><td align="center" valign="top" rowspan="1" colspan="1">54 (24)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (23)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body weight, kg</td><td align="center" valign="top" rowspan="1" colspan="1">97&#x02009;&#x000b1;&#x02009;23</td><td align="center" valign="top" rowspan="1" colspan="1">97&#x02009;&#x000b1;&#x02009;19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">33&#x02009;&#x000b1;&#x02009;6</td><td align="center" valign="top" rowspan="1" colspan="1">33&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c, %</td><td align="center" valign="top" rowspan="1" colspan="1">8.5&#x02009;&#x000b1;&#x02009;1.0</td><td align="center" valign="top" rowspan="1" colspan="1">8.5&#x02009;&#x000b1;&#x02009;1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c, mmol/mol</td><td align="center" valign="top" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;11</td><td align="center" valign="top" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting plasma glucose, mg/dL</td><td align="center" valign="top" rowspan="1" colspan="1">181&#x02009;&#x000b1;&#x02009;45</td><td align="center" valign="top" rowspan="1" colspan="1">184&#x02009;&#x000b1;&#x02009;47</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting plasma glucose, mmol/L</td><td align="center" valign="top" rowspan="1" colspan="1">10.0&#x02009;&#x000b1;&#x02009;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">10.2&#x02009;&#x000b1;&#x02009;2.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type 2 diabetes duration, years</td><td align="center" valign="top" rowspan="1" colspan="1">9&#x02009;&#x000b1;&#x02009;6</td><td align="center" valign="top" rowspan="1" colspan="1">8&#x02009;&#x000b1;&#x02009;6</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Renal function<xref ref-type="fn" rid="dom13056-note-0005">a</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Normal</td><td align="center" valign="top" rowspan="1" colspan="1">85 (37)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (38)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mild impairment</td><td align="center" valign="top" rowspan="1" colspan="1">113 (49)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (52)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Moderate impairment</td><td align="center" valign="top" rowspan="1" colspan="1">29 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (10)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Diabetes management method at screening</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No use of sulfonylurea at screening</td><td align="center" valign="top" rowspan="1" colspan="1">140 (61)</td><td align="center" valign="top" rowspan="1" colspan="1">86 (59)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Diet and exercise</td><td align="center" valign="top" rowspan="1" colspan="1">31 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (12)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Metformin alone</td><td align="center" valign="top" rowspan="1" colspan="1">102 (45)</td><td align="center" valign="top" rowspan="1" colspan="1">65 (45)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Thiazolidinedione alone</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Metformin&#x02009;+&#x02009;thiazolidinedione</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Use of sulfonylurea at screening</td><td align="center" valign="top" rowspan="1" colspan="1">89 (39)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (41)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Sulfonylurea alone</td><td align="center" valign="top" rowspan="1" colspan="1">8 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (4)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Sulfonylurea&#x02009;+&#x02009;metformin</td><td align="center" valign="top" rowspan="1" colspan="1">76 (33)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (36)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Sulfonylurea&#x02009;+&#x02009;thiazolidinedione</td><td align="center" valign="top" rowspan="1" colspan="1">1 (&#x0003c;1)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Sulfonylurea + metformin + thiazolidinedione</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1)</td></tr></tbody></table><table-wrap-foot><fn id="dom13056-note-0003"><p>Abbreviations: BID, twice daily; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; QWS&#x02010;AI, once&#x02010;weekly suspension by autoinjector.</p></fn><fn id="dom13056-note-0004"><p>Continuous variables are presented as mean &#x000b1; standard deviation; categorical variables are presented as n (%).</p></fn><fn id="dom13056-note-0005"><label>a</label><p>Normal function: eGFR &#x02265;90 mL/min/1.73 m<sup>2</sup>; mild impairment: eGFR 60 to 89 mL/min/1.73 m<sup>2</sup>; moderate impairment: eGFR 30 to 59 mL/min/1.73 m<sup>2</sup>; severe impairment: eGFR &#x0003c;30 mL/min/1.73 m<sup>2</sup>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom13056-sec-0012"><label>3.2</label><title>Primary and secondary efficacy end points</title><p>HbA1c was reduced with both exenatide QWS&#x02010;AI (&#x02212;1.39%&#x02009;&#x000b1;&#x02009;0.09% [&#x02212;15&#x02009;&#x000b1;&#x02009;1&#x02009;mmol/mol]) and exenatide BID treatment (&#x02212;1.02%&#x02009;&#x000b1;&#x02009;0.11% [&#x02212;11&#x02009;&#x000b1;&#x02009;1&#x02009;mmol/mol]) (Figure <xref rid="dom13056-fig-0002" ref-type="fig">2</xref>A). The reduction in HbA1c after 28&#x02009;weeks was significantly greater with exenatide QWS&#x02010;AI (difference, &#x02212;0.37%&#x02009;&#x000b1;&#x02009;0.13% [&#x02212;4&#x02009;&#x000b1;&#x02009;1&#x02009;mmol/mol]; 95% confidence interval [CI], &#x02212;0.63% to &#x02212;0.10%; <italic>P</italic>&#x02009;=&#x02009;.0072). Thus, the superiority of exenatide QWS&#x02010;AI over exenatide BID was demonstrated.</p><fig fig-type="Figure" xml:lang="en" id="dom13056-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">HbA1c</styled-content> over time (<styled-content style="fixed-case">mITT</styled-content> population). <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">P</styled-content>robability density function of <styled-content style="fixed-case">HbA1c</styled-content> (<styled-content style="fixed-case">mITT</styled-content> population). <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">FPG</styled-content> over time (<styled-content style="fixed-case">mITT</styled-content> population). <styled-content style="fixed-case">D</styled-content>, <styled-content style="fixed-case">C</styled-content>hange in body weight over time (<styled-content style="fixed-case">mITT</styled-content> population). <styled-content style="fixed-case">E</styled-content>, <styled-content style="fixed-case">P</styled-content>lasma glucose during meal test (meal test&#x02013;evaluable population). <styled-content style="fixed-case">F</styled-content>, <styled-content style="fixed-case">P</styled-content>lasma exenatide concentration for patients with antibody titers &#x02264;625. Dotted line indicates minimum effective concentration of exenatide for glucose lowering (~50&#x02009;pg/mL). *<styled-content style="italic-in-any-context">P</styled-content>&#x02009;&#x0003c;&#x02009;.05 vs exenatide <styled-content style="fixed-case">BID</styled-content>. <sup>&#x02020;</sup>
<styled-content style="italic-in-any-context">P</styled-content>&#x02009;&#x02264;&#x02009;.01 vs exenatide <styled-content style="fixed-case">BID</styled-content>. <sup>&#x02021;</sup>
<styled-content style="italic-in-any-context">P</styled-content>&#x02009;&#x02264;&#x02009;.001 vs exenatide <styled-content style="fixed-case">BID</styled-content>. Abbreviations: <styled-content style="fixed-case">BID</styled-content>, twice daily; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">LS</styled-content>, least&#x02010;squares; <styled-content style="fixed-case">mITT</styled-content>, modified intention&#x02010;to&#x02010;treat; <styled-content style="fixed-case">QWS&#x02010;AI</styled-content>, once&#x02010;weekly suspension by autoinjector; <styled-content style="fixed-case">SD</styled-content>, standard deviation; <styled-content style="fixed-case">SE</styled-content>, standard error</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-20-165-g001"/></fig><p>Certain patient demographic characteristics were tested for interaction with the treatment difference between exenatide QWS&#x02010;AI and exenatide BID. No treatment interaction was found for age or sex, but a significant treatment interaction was found for race (treatment&#x02010;by&#x02010;week&#x02010;by&#x02010;race, <italic>P</italic>&#x02009;=&#x02009;.0007). HbA1c was reduced by &#x02212;1.5% and &#x02212;1.0% (&#x02212;16 and &#x02212;11&#x02009;mmol/mol; n&#x02009;=&#x02009;278) in white patients, by &#x02212;1.1% and &#x02212;0.9% (&#x02212;12 and &#x02212;10&#x02009;mmol/mol; n&#x02009;=&#x02009;25) in Asian patients, and by &#x02212;1.0% and &#x02212;1.1% (&#x02212;11 and &#x02212;12&#x02009;mmol/mol; n&#x02009;=&#x02009;61) in black patients treated with exenatide QWS&#x02010;AI and exenatide BID, respectively.</p><p>After 28&#x02009;weeks, the shift in probability density function suggested that more patients receiving exenatide QWS&#x02010;AI vs exenatide BID had HbA1c values between 4.0% and 8.0% (20 and 64&#x02009;mmol/mol) and fewer patients had HbA1c values between 8.0% and 12.0% (64 and 108&#x02009;mmol/mol) (Figure <xref rid="dom13056-fig-0002" ref-type="fig">2</xref>B). However, there was no statistical difference in the proportion of patients who achieved HbA1c&#x02009;&#x0003c;7.0% (&#x0003c;53&#x02009;mmol/mol) with exenatide QWS&#x02010;AI (49.3%) or exenatide BID (43.2%; <italic>P</italic>&#x02009;=&#x02009;.225) and, although a greater proportion of patients achieved HbA1c&#x02009;&#x02264;6.5% (&#x02264; 48&#x02009;mmol/mol; <italic>P</italic>&#x02009;=&#x02009;.051) with exenatide QWS&#x02010;AI (35.8%) than with exenatide BID (26.0%), this difference also did not reach significance.</p><p>FPG decreased comparably with both treatments by week 2 (the first post&#x02010;baseline measurement) and remained below baseline for the duration of the study (Figure <xref rid="dom13056-fig-0002" ref-type="fig">2</xref>C). After 28&#x02009;weeks, the change in FPG was &#x02212;32.7&#x02009;&#x000b1;&#x02009;3.9&#x02009;mg/dL (&#x02212;1.81&#x02009;&#x000b1;&#x02009;0.22&#x02009;mmol/L) for exenatide QWS&#x02010;AI and &#x02212;22.5&#x02009;&#x000b1;&#x02009;4.9&#x02009;mg/dL (&#x02212;1.25&#x02009;&#x000b1;&#x02009;0.27&#x02009;mmol/L) for exenatide BID (difference, &#x02212;10.2&#x02009;&#x000b1;&#x02009;5.8&#x02009;mg/dL [&#x02212;0.57&#x02009;&#x000b1;&#x02009;0.32&#x02009;mmol/L]; <italic>P</italic>&#x02009;=&#x02009;.083).</p><p>Body weight was reduced from baseline with both exenatide QWS&#x02010;AI (&#x02212;1.49&#x02009;&#x000b1;&#x02009;0.28&#x02009;kg) and exenatide BID (&#x02212;1.89&#x02009;&#x000b1;&#x02009;0.36&#x02009;kg) (Figure <xref rid="dom13056-fig-0002" ref-type="fig">2</xref>D). After 28&#x02009;weeks, there was no significant between&#x02010;group difference in change in body weight (difference, 0.4&#x02009;&#x000b1;&#x02009;0.4&#x02009;kg; <italic>P</italic>&#x02009;=&#x02009;.37).</p><p>For patients who participated in the meal test, 2&#x02010;hour PPG was reduced by week 16 with exenatide QWS&#x02010;AI (&#x02212;87.0&#x02009;&#x000b1;&#x02009;12.8&#x02009;mg/dL [&#x02212;4.83&#x02009;&#x000b1;&#x02009;0.71&#x02009;mmol/L]) and exenatide BID (&#x02212;113.7&#x02009;&#x000b1;&#x02009;14.8&#x02009;mg/dL [&#x02212;6.31&#x02009;&#x000b1;&#x02009;0.82&#x02009;mmol/L]; difference, 26.7&#x02009;&#x000b1;&#x02009;15.9 [1.48&#x02009;&#x000b1;&#x02009;0.88&#x02009;mmol/L]; nominal <italic>P</italic>&#x02009;=&#x02009;.0999).</p></sec><sec id="dom13056-sec-0013"><label>3.3</label><title>Additional efficacy end points</title><p>Fasting insulin concentrations increased by 6.8&#x02009;&#x000b1;&#x02009;1.8&#x02009;pmol/L with exenatide QWS&#x02010;AI and by 2.5&#x02009;&#x000b1;&#x02009;2.2&#x02009;pmol/L with exenatide BID (difference, 4.3&#x02009;&#x000b1;&#x02009;2.7&#x02009;pmol/L; nominal <italic>P</italic>&#x02009;=&#x02009;.11). Fasting glucagon concentrations increased by 7.5&#x02009;&#x000b1;&#x02009;3.1&#x02009;pmol/L with exenatide QWS&#x02010;AI and by 6.9&#x02009;&#x000b1;&#x02009;3.8&#x02009;pmol/L with exenatide BID (difference, 0.6&#x02009;&#x000b1;&#x02009;4.6&#x02009;pmol/L; nominal <italic>P</italic>&#x02009;=&#x02009;.89).</p><p>Both treatments reduced pre&#x02010;meal glucose and post&#x02010;meal excursion values after a standardized meal (Figure <xref rid="dom13056-fig-0002" ref-type="fig">2</xref>E). However, treatment with exenatide QWS&#x02010;AI resulted in a greater reduction in pre&#x02010;meal glucose, whereas treatment with exenatide BID resulted in a greater reduction in post&#x02010;meal excursions, although neither difference was statistically significant. Postprandial insulin was enhanced with exenatide QWS&#x02010;AI compared with exenatide BID after 16&#x02009;weeks of treatment (Table S1, Appendix S1). Postprandial serum triglycerides decreased after 16&#x02009;weeks with both exenatide QWS&#x02010;AI and exenatide BID, with a greater decrease in postprandial lipaemia with exenatide BID (Table S1, Appendix S1).</p></sec><sec id="dom13056-sec-0014"><label>3.4</label><title>Efficacy with sulfonylurea use</title><p>The use of sulfonylurea (exenatide QWS&#x02010;AI, n&#x02009;=&#x02009;89; exenatide BID, n&#x02009;=&#x02009;60) vs no use of sulfonylurea (exenatide QWS&#x02010;AI, n&#x02009;=&#x02009;140; exenatide BID, n&#x02009;=&#x02009;86) was associated with a lesser reduction in HbA1c, FPG and body weight for both treatments (Figure S1, Appendix S1). A treatment&#x02010;by&#x02010;sulfonylurea use interaction was not significant for the change in HbA1c (<italic>P</italic>&#x02009;=&#x02009;.21) or body weight (<italic>P</italic>&#x02009;=&#x02009;.068) but was significant for the change in FPG over 28&#x02009;weeks (<italic>P</italic>&#x02009;=&#x02009;.024), indicating that sulfonylurea use was associated with a lesser FPG response to exenatide.</p></sec><sec id="dom13056-sec-0015"><label>3.5</label><title>Cardiovascular risk factors</title><p>Several cardiovascular risk factors were evaluated after 28&#x02009;weeks (Table S2, Appendix S1). Both exenatide QWS&#x02010;AI (&#x02212;0.8&#x02009;&#x000b1;&#x02009;1.1&#x02009;mm Hg) and exenatide BID (&#x02212;1.6&#x02009;&#x000b1;&#x02009;1.4&#x02009;mm Hg) recipients had reductions in systolic BP (difference, 0.8&#x02009;&#x000b1;&#x02009;1.6&#x02009;mm Hg; nominal <italic>P</italic>&#x02009;=&#x02009;.61). Diastolic BP increased slightly with exenatide QWS&#x02010;AI and decreased with exenatide BID (difference, 2.0&#x02009;&#x000b1;&#x02009;0.9&#x02009;mm Hg; nominal <italic>P</italic>&#x02009;=&#x02009;.03). Heart rate increased slightly in both groups (mean&#x02009;&#x000b1;&#x02009;SD: exenatide QWS&#x02010;AI, 1.9&#x02009;&#x000b1;&#x02009;9.4&#x02009;beats/min; exenatide BID, 1.6&#x02009;&#x000b1;&#x02009;8.5&#x02009;beats/min). There were no clinically meaningful changes in fasting lipids or other cardiovascular risk factors, including high&#x02010;sensitivity C&#x02010;reactive protein, brain natriuretic peptide or urinary albumin/creatinine ratio (data not shown).</p></sec><sec id="dom13056-sec-0016"><label>3.6</label><title>Safety and tolerability results</title><p>The most common AEs were gastrointestinal in nature (Table <xref rid="dom13056-tbl-0002" ref-type="table-wrap">2</xref>) and occurred more often with exenatide BID than with exenatide QWS&#x02010;AI. The proportion of patients with gastrointestinal AEs was lower with exenatide QWS&#x02010;AI (n&#x02009;=&#x02009;52/229; 22.7%) than with exenatide BID (n&#x02009;=&#x02009;52/146; 35.6%); most gastrointestinal AEs in both groups were of mild or moderate intensity. Injection site&#x02010;related AEs were more frequent overall with exenatide QWS&#x02010;AI (n&#x02009;=&#x02009;61/229; 26.6%) than with exenatide BID (n&#x02009;=&#x02009;6/146; 4.1%). Nodules were the most common injection site&#x02010;related AE in the exenatide QWS&#x02010;AI group (n&#x02009;=&#x02009;29/229; 12.7%) but were less frequent with exenatide BID (n&#x02009;=&#x02009;1/146; 0.7%); in most cases, nodules were single events, of mild intensity, and were reported during the first 60&#x02009;days of treatment. Other injection site&#x02010;related AEs, occurring in &#x02265;3% of patients in the exenatide QWS&#x02010;AI and exenatide BID groups, respectively, were pruritus (4.4% [n&#x02009;=&#x02009;10/229] vs 0.7% [n&#x02009;=&#x02009;1/146]), erythema (3.5% [n&#x02009;=&#x02009;8/229] vs 0.7% [n&#x02009;=&#x02009;1/146]), injection&#x02010;site mass (3.1% [n&#x02009;=&#x02009;7/229] vs 0.0% [n&#x02009;=&#x02009;0/146]) and pain (3.1% [n&#x02009;=&#x02009;7/229] vs 0.0% [n&#x02009;=&#x02009;0/146]). Of note, there were fewer withdrawals because of AEs among patients treated with exenatide QWS&#x02010;AI (n&#x02009;=&#x02009;6/229; 2.6%) than with exenatide BID (n&#x02009;=&#x02009;8/148; 5.4%).</p><table-wrap id="dom13056-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Incidence of <styled-content style="fixed-case">AE</styled-content>s and hypoglycaemia (all treated population)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Exenatide QWS&#x02010;AI (n&#x02009;=&#x02009;229)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Exenatide BID (n&#x02009;=&#x02009;146)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">All patients with AEs</td><td align="center" valign="top" rowspan="1" colspan="1">162 (70.7)</td><td align="center" valign="top" rowspan="1" colspan="1">108 (74.0)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">AEs occurring in &#x02265;5% of patients</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td align="center" valign="top" rowspan="1" colspan="1">22 (9.6)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (21.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Injection&#x02010;site nodule</td><td align="center" valign="top" rowspan="1" colspan="1">29 (12.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">12 (5.2)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (11.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.7)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (6.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Upper respiratory tract infection</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.7)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (3.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="center" valign="top" rowspan="1" colspan="1">8 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (6.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients with serious AEs</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (4.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patients with AEs leading to withdrawal</td><td align="center" valign="top" rowspan="1" colspan="1">11 (4.8)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (7.5)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Hypoglycaemia</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">With concomitant sulfonylurea use<xref ref-type="fn" rid="dom13056-note-0008">a</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;89</td><td align="center" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;60</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Major hypoglycaemia</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Minor hypoglycaemia</td><td align="center" valign="top" rowspan="1" colspan="1">22 (24.7)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (18.3)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Symptoms of hypoglycaemia</td><td align="center" valign="top" rowspan="1" colspan="1">24 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (25.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Without concomitant sulfonylurea use<xref ref-type="fn" rid="dom13056-note-0008">a</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;140</td><td align="center" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;86</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Major hypoglycaemia</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Minor hypoglycaemia</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3.5)</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Symptoms of hypoglycaemia</td><td align="center" valign="top" rowspan="1" colspan="1">12 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.8)</td></tr></tbody></table><table-wrap-foot><fn id="dom13056-note-0006"><p>Abbreviations: AE, adverse event; BID, twice daily; QWS&#x02010;AI, once&#x02010;weekly suspension by autoinjector.</p></fn><fn id="dom13056-note-0007"><p>Data are given as n (%).</p></fn><fn id="dom13056-note-0008"><label>a</label><p>At screening.</p></fn></table-wrap-foot></table-wrap><p>No severe hypoglycaemia occurred during the study. Minor hypoglycaemia occurred most often with concomitant sulfonylurea use. Six patients (2.6%) receiving exenatide QWS&#x02010;AI and 7 patients (4.8%) receiving exenatide BID experienced serious AEs; most serious AEs were considered not related to study treatment by the investigator. Of interest, 1 patient treated with exenatide QWS&#x02010;AI experienced a serious AE of myocardial infarction and 1 experienced pancreatitis, both of which were confirmed by adjudication. One patient treated with exenatide BID experienced a serious AE of basal cell carcinoma (adjudicated), 1 patient experienced uterine leiomyoma and 1 patient experienced acute renal failure (while also experiencing serious AEs of lactic acidosis, septic shock and toxic encephalopathy on the same day). There were no meaningful changes in laboratory safety parameters.</p><p>Among patients with available antibody data at week 28, 53.9% of patients treated with exenatide QWS&#x02010;AI and 28.8% of patients treated with exenatide BID were positive for exenatide antibodies. The majority of these patients displayed low titers, and antibody status had no observable impact on the change in HbA1c over 28&#x02009;weeks (Table S3, Appendix S1).</p></sec><sec id="dom13056-sec-0017"><label>3.7</label><title>Pharmacokinetics</title><p>The pharmacokinetic&#x02010;evaluable population consisted of 191 patients treated with exenatide QWS&#x02010;AI. Samples with the highest antibody titers (&#x0003e;625) were excluded because of the potential for antibodies to interfere with the assay. Plasma exenatide concentrations increased from baseline through week 10, at which point steady state was achieved and concentrations remained relatively stable (Figure <xref rid="dom13056-fig-0002" ref-type="fig">2</xref>F).</p></sec></sec><sec id="dom13056-sec-0018"><label>4</label><title>DISCUSSION</title><p>Longer&#x02010;acting GLP&#x02010;1RAs developed after exenatide BID, the first&#x02010;in&#x02010;class GLP&#x02010;1RA, have been administered with reduced injection frequency or with simpler injection devices to improve ease of use and patient satisfaction. This study compared administration of a long&#x02010;acting, soluble formulation of exenatide dosed QW using an autoinjector (exenatide QWS&#x02010;AI) vs the short&#x02010;acting, BID formulation (exenatide BID) over 28&#x02009;weeks. Although HbA1c was significantly reduced with both formulations, the HbA1c reduction was significantly greater with exenatide QWS&#x02010;AI than with exenatide BID. A comparable number of patients achieved HbA1c targets with exenatide QWS&#x02010;AI and exenatide BID. Although there were clinically relevant reductions from baseline in FPG, body weight and 2&#x02010;hour PPG with both treatments, there were no significant differences between formulations. Fasting insulin and glucagon concentrations increased and postprandial triglycerides decreased with both formulations after 16&#x02009;weeks. Gastrointestinal AEs were the most common AE overall, but fewer events occurred in the exenatide QWS&#x02010;AI group. Injection site&#x02010;related AEs occurred more often with exenatide QWS&#x02010;AI than with exenatide BID, as anticipated because of the microspheres in the long&#x02010;acting formulation. Compliance was high among both groups and was therefore unlikely to have affected the HbA1c differences between groups. Thus, exenatide QWS&#x02010;AI is a potential alternative to exenatide BID for the treatment of type 2 diabetes.</p><p>The differences in treatment effects for exenatide QWS&#x02010;AI and exenatide BID are consistent with their different pharmacokinetic profiles. Exenatide QWS&#x02010;AI, which releases exenatide from microspheres over 10&#x02009;weeks, is long acting and stimulates insulin secretion between doses, improving FPG.<xref rid="dom13056-bib-0007" ref-type="ref">7</xref> In contrast, short&#x02010;acting exenatide BID (half&#x02010;life, 2.1&#x02009;hours), which is administered before the 2 largest meals each day, affects PPG by temporarily stimulating insulin secretion and delaying gastric emptying.<xref rid="dom13056-bib-0007" ref-type="ref">7</xref>, <xref rid="dom13056-bib-0008" ref-type="ref">8</xref> The DURATION&#x02010;1 and DURATION&#x02010;5 studies, which compared exenatide QW and exenatide BID, found that exenatide QW resulted in significantly greater reductions in HbA1c and FPG.<xref rid="dom13056-bib-0009" ref-type="ref">9</xref>, <xref rid="dom13056-bib-0010" ref-type="ref">10</xref> In DURATION&#x02010;1, exenatide BID resulted in a significantly greater reduction in 2&#x02010;hour PPG (data not reported for DURATION&#x02010;5). Although the reductions in FPG and 2&#x02010;hour PPG were not significantly different between exenatide QWS&#x02010;AI and exenatide BID for the current study, the trends are consistent with the DURATION&#x02010;1 and DURATION&#x02010;5 findings.</p><p>Exenatide BID is a well&#x02010;established comparator or &#x0201c;standard&#x0201d; for new members of the GLP&#x02010;1RA class. Other studies comparing exenatide BID with long&#x02010;acting or continuously acting GLP&#x02010;1RAs, including liraglutide,<xref rid="dom13056-bib-0011" ref-type="ref">11</xref> albiglutide<xref rid="dom13056-bib-0012" ref-type="ref">12</xref> and dulaglutide,<xref rid="dom13056-bib-0013" ref-type="ref">13</xref> have also demonstrated generally greater efficacy in reducing HbA1c and FPG, with lesser effects on PPG, for long&#x02010;acting GLP&#x02010;1RAs compared with exenatide BID. Consistent with the known weight&#x02010;loss effects of the GLP&#x02010;1RA class,<xref rid="dom13056-bib-0014" ref-type="ref">14</xref>, <xref rid="dom13056-bib-0015" ref-type="ref">15</xref> weight loss was similar between long&#x02010;acting GLP&#x02010;1RAs and exenatide BID. Thus, the findings of the current study are consistent with those of others comparing long&#x02010;acting GLP&#x02010;1RAs with exenatide BID.</p><p>GLP&#x02010;1RAs differ in safety profiles. Similar to the current study, in a pooled analysis comparing long&#x02010;acting (exenatide QW, liraglutide) and short&#x02010;acting (exenatide BID) GLP&#x02010;1RAs, upper gastrointestinal AEs, most commonly nausea and vomiting, appeared less frequently with exenatide QW or liraglutide than with exenatide BID.<xref rid="dom13056-bib-0016" ref-type="ref">16</xref> Diarrhea occurred at a similar frequency. The improved tolerability of the long&#x02010;acting formulations of exenatide may be related to the gradual increase in plasma concentration from the microspheres, which provides a natural titration process.<xref rid="dom13056-bib-0002" ref-type="ref">2</xref> However, the microsphere formulation contributed to the increased frequency of injection&#x02010;site reactions reported in the current study with exenatide QWS&#x02010;AI compared with exenatide BID, because the drug being administered was the same. The DURATION&#x02010;1<xref rid="dom13056-bib-0009" ref-type="ref">9</xref> and DURATION&#x02010;5<xref rid="dom13056-bib-0010" ref-type="ref">10</xref> studies also found injection&#x02010;site reactions to occur more frequently with exenatide QW than with exenatide BID.</p><p>In addition to increasing the incidence of hypoglycaemia, the current study found concomitant sulfonylurea use to be associated with reduced efficacy, of both exenatide QWS&#x02010;AI and exenatide BID. The EUREXA study, which compared exenatide BID with glimepiride (a sulfonylurea), found that treatment failure was less common with exenatide BID than with glimepiride (41% with exenatide BID, 54% with glimepiride; <italic>P</italic>&#x02009;=&#x02009;.002).<xref rid="dom13056-bib-0017" ref-type="ref">17</xref> HbA1c was also reduced significantly more with exenatide BID treatment than with a sulfonylurea. It is possible that sulfonylurea use in combination with a GLP&#x02010;1RA, as well as in monotherapy, negatively affects treatment response over time. Alternatively, patients taking a sulfonylurea may have more advanced type 2 diabetes than patients undergoing monotherapy, or may experience a more rapid decline in beta&#x02010;cell function.<xref rid="dom13056-bib-0018" ref-type="ref">18</xref>
</p><p>This study has limitations. The open&#x02010;label design may have contributed to bias in the study conduct and patient behaviors. Proportionately, more patients withdrew from the exenatide BID group. In addition, the sample size was too small for conclusions to be made on potential interactions between demographic characteristics and response to therapy, and the imbalance in the randomization ratio may have affected the power for primary and secondary end points. Diet and exercise behaviors were not recorded.</p><p>Overall, this study found that both the new formulation (exenatide QWS&#x02010;AI) and exenatide BID improved glycaemic control and reduced body weight in patients with type 2 diabetes. However, treatment with exenatide QWS&#x02010;AI resulted in a greater improvement in HbA1c. Although not statistically significant, there was a greater reduction in FPG with exenatide QWS&#x02010;AI and a greater reduction in 2&#x02010;hour PPG with exenatide BID. This pattern of efficacy is characteristic for a long&#x02010;acting GLP&#x02010;1RA. Additionally, exenatide QWS&#x02010;AI was associated with an improved AE profile and fewer treatment discontinuations than was exenatide BID.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13056-supitem-0001"><caption><p>
<bold>Appendix S1.</bold>
</p></caption><media xlink:href="DOM-20-165-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13056-sec-0019"><title>ACKNOWLEDGEMENTS</title><p>This study was supported by Bristol&#x02010;Myers Squibb and AstraZeneca. Mollie Marko PhD, of inScience Communications, Springer Healthcare (New York, New York, USA), provided medical writing support funded by AstraZeneca.</p><p>This work was presented previously at the International Congress of Endocrinology (ICE), June 21 to 24, 2014, San Francisco, California: Wysham CH, Rosenstock J, Malloy J, Vetter M, He Y, &#x000d6;hman P, Iqbal N. DURATION&#x02010;NEO&#x02010;1: Greater A1C reductions with exenatide suspension once weekly by autoinjector pen vs exenatide twice daily in inadequately controlled type 2 diabetes.</p><sec id="dom13056-sec-0020" sec-type="COI-statement"><title>Conflict of interest</title><p>C. H. W. has received research support and served as a consultant, advisor and speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk and Sanofi. J. R. has received research support from AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, Intarcia, Janssen, Lexicon, Merck, Novo Nordisk, Pfizer and Sanofi, and has served on advisory boards of, or received consulting honoraria from, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Intarcia, Janssen, Merck, Novo Nordisk and Sanofi. M. L. V. was an employee of Bristol&#x02010;Myers Squibb during the conduct of the study. N. I. and P. &#x000d6;. are employees of AstraZeneca. F. D. was an employee of AstraZeneca during the development of this manuscript.</p></sec><sec id="dom13056-sec-0021"><title>Author contributions</title><p>C. H. W., N. I. and F.D. contributed to the acquisition, analysis and interpretation of data and the outline and revision of the manuscript. J. R., M. L. V. and N. I. contributed to the outline of the manuscript, and were involved in the writing and discussion of the manuscript, analyses and interpretation of the data, and all critical revisions of the manuscript. P. &#x000d6;. is the guarantor of the work and takes full responsibility for the contents.</p></sec></ack><ref-list id="dom13056-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13056-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="dom13056-cit-0002">BYDUREON (Exenatide Extended&#x02010;Release) for Injectable Suspension: US Prescribing Information. Wilmington, Delaware: AstraZeneca Pharmaceuticals LP; <year>2017</year>
<ext-link ext-link-type="uri" xlink:href="https://www.azpicentral.com/bydureon/pi_bydureon.pdf#page=1">https://www.azpicentral.com/bydureon/pi_bydureon.pdf#page=1</ext-link>. Accessed June 28, 2017.</mixed-citation></ref><ref id="dom13056-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom13056-cit-0003">
<string-name>
<surname>Fineman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Flanagan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Pharmacokinetics and pharmacodynamics of exenatide extended&#x02010;release after single and multiple dosing</article-title>. <source>Clin Pharmacokinet</source>. <year>2011</year>;<volume>50</volume>:<fpage>65</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">21142268</pub-id></mixed-citation></ref><ref id="dom13056-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom13056-cit-0004">
<string-name>
<surname>Wysham</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>MacConell</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Maggs</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Trautmann</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Five&#x02010;year efficacy and safety data of exenatide once weekly: long&#x02010;term results from the DURATION&#x02010;1 randomized clinical trial</article-title>. <source>Mayo Clin Proc</source>. <year>2015</year>;<volume>90</volume>:<fpage>356</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">25744115</pub-id></mixed-citation></ref><ref id="dom13056-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom13056-cit-0005">
<string-name>
<surname>Henry</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Iqbal</surname>
<given-names>N</given-names>
</string-name>. <article-title>Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open&#x02010;label extension of the DURATION&#x02010;1 study</article-title>. <source>Diabetes Technol Ther</source>. <year>2016</year>;<volume>18</volume>:<fpage>677</fpage>&#x02013;<lpage>686</lpage>.<pub-id pub-id-type="pmid">27525540</pub-id></mixed-citation></ref><ref id="dom13056-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="dom13056-cit-0006">BYETTA (Exenatide) Injection: US Prescribing Information. Wilmington, Delaware: AstraZeneca Pharmaceuticals, LP; <year>2015</year>
<ext-link ext-link-type="uri" xlink:href="https://www.azpicentral.com/byetta/pi_byetta.pdf#page=1">https://www.azpicentral.com/byetta/pi_byetta.pdf#page=1</ext-link>. Accessed June 28, 2017.</mixed-citation></ref><ref id="dom13056-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom13056-cit-0007">
<string-name>
<surname>Fineman</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Mace</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Clinical relevance of anti&#x02010;exenatide antibodies: safety, efficacy and cross&#x02010;reactivity with long&#x02010;term treatment</article-title>. <source>Diabetes Obes Metab</source>. <year>2012</year>;<volume>14</volume>:<fpage>546</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">22236356</pub-id></mixed-citation></ref><ref id="dom13056-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13056-cit-0008">
<string-name>
<surname>Meier</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>GLP&#x02010;1 receptor agonists for individualized treatment of type 2 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. <year>2012</year>;<volume>8</volume>:<fpage>728</fpage>&#x02013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">22945360</pub-id></mixed-citation></ref><ref id="dom13056-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13056-cit-0009">
<string-name>
<surname>Marathe</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Rayner</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</string-name>. <article-title>Relationships between gastric emptying, postprandial glycemia, and incretin hormones</article-title>. <source>Diabetes Care</source>. <year>2013</year>;<volume>36</volume>:<fpage>1396</fpage>&#x02013;<lpage>1405</lpage>.<pub-id pub-id-type="pmid">23613599</pub-id></mixed-citation></ref><ref id="dom13056-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13056-cit-0010">
<string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open&#x02010;label, non&#x02010;inferiority study</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>:<fpage>1240</fpage>&#x02013;<lpage>1250</lpage>.<pub-id pub-id-type="pmid">18782641</pub-id></mixed-citation></ref><ref id="dom13056-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13056-cit-0011">
<string-name>
<surname>Blevins</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pullman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Malloy</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>DURATION&#x02010;5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>:<fpage>1301</fpage>&#x02013;<lpage>1310</lpage>.<pub-id pub-id-type="pmid">21307137</pub-id></mixed-citation></ref><ref id="dom13056-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13056-cit-0012">
<string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sesti</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26&#x02010;week randomised, parallel&#x02010;group, multinational, open&#x02010;label trial (LEAD&#x02010;6)</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>:<fpage>39</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19515413</pub-id></mixed-citation></ref><ref id="dom13056-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13056-cit-0013">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Reusch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bush</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>M</given-names>
</string-name>. <article-title>Albiglutide study group. Potential of albiglutide, a long&#x02010;acting GLP&#x02010;1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing</article-title>. <source>Diabetes Care</source>. <year>2009</year>;<volume>32</volume>:<fpage>1880</fpage>&#x02013;<lpage>1886</lpage>.<pub-id pub-id-type="pmid">19592625</pub-id></mixed-citation></ref><ref id="dom13056-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13056-cit-0014">
<string-name>
<surname>Wysham</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Blevins</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Arakaki</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD&#x02010;1)</article-title>. <source>Diabetes Care</source>. <year>2014</year>;<volume>37</volume>:<fpage>2159</fpage>&#x02013;<lpage>2167</lpage>.<pub-id pub-id-type="pmid">24879836</pub-id></mixed-citation></ref><ref id="dom13056-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom13056-cit-0015">
<string-name>
<surname>Sun</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Effects of glucagon&#x02010;like peptide&#x02010;1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta&#x02010;analysis</article-title>. <source>J Diabetes Res</source>. <year>2015</year>;<volume>2015</volume>:<fpage>157201</fpage>.<pub-id pub-id-type="pmid">25688373</pub-id></mixed-citation></ref><ref id="dom13056-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13056-cit-0016">
<string-name>
<surname>Potts</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Khunti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bodicoat</surname>
<given-names>DH</given-names>
</string-name>. <article-title>The effect of glucagon&#x02010;like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta&#x02010;analysis</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0126769</fpage>.<pub-id pub-id-type="pmid">26121478</pub-id></mixed-citation></ref><ref id="dom13056-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom13056-cit-0017">
<string-name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aroda</surname>
<given-names>VR</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rayner</surname>
<given-names>CK</given-names>
</string-name>. <article-title>Upper and/or lower gastrointestinal adverse events with glucagon&#x02010;like peptide&#x02010;1 receptor agonists: incidences and consequences</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>:<fpage>672</fpage>&#x02013;<lpage>681</lpage>.<pub-id pub-id-type="pmid">28058769</pub-id></mixed-citation></ref><ref id="dom13056-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom13056-cit-0018">
<string-name>
<surname>Gallwitz</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dotta</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open&#x02010;label, randomised controlled trial</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>379</volume>:<fpage>2270</fpage>&#x02013;<lpage>2278</lpage>.<pub-id pub-id-type="pmid">22683137</pub-id></mixed-citation></ref><ref id="dom13056-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom13056-cit-0019">
<string-name>
<surname>Shin</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>JH</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>CH</given-names>
</string-name>, et al. <article-title>The duration of sulfonylurea treatment is associated with beta&#x02010;cell dysfunction in patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Technol Ther</source>. <year>2012</year>;<volume>14</volume>:<fpage>1033</fpage>&#x02013;<lpage>1042</lpage>.<pub-id pub-id-type="pmid">22958196</pub-id></mixed-citation></ref></ref-list></back></article>